Published in Br J Pharmacol on March 01, 2003
NO+, NO, and NO- donation by S-nitrosothiols: implications for regulation of physiological functions by S-nitrosylation and acceleration of disulfide formation. Arch Biochem Biophys (1995) 2.70
Primary pulmonary hypertension. Lancet (1998) 2.47
Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol (1996) 2.27
Mechanism of nitric oxide release from S-nitrosothiols. J Biol Chem (1996) 2.02
Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther (2001) 1.68
Biological activity of S-nitrosothiols: the role of nitric oxide. J Pharmacol Exp Ther (1993) 1.51
The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Mol Pharmacol (1999) 1.42
Methylene blue inhibits vasodilation of skeletal muscle arterioles to acetylcholine and nitric oxide via the extracellular generation of superoxide anion. J Pharmacol Exp Ther (1990) 1.21
Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion. Br J Pharmacol (2001) 1.20
Methylene blue inhibits nitrovasodilator- and endothelium-derived relaxing factor-induced cyclic GMP accumulation in cultured pulmonary arterial smooth muscle cells via generation of superoxide anion. J Pharmacol Exp Ther (1992) 1.18
Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol (1995) 1.17
Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun (2000) 1.16
Differential effects of hydroxocobalamin on relaxations induced by nitrosothiols in rat aorta and anococcygeus muscle. Eur J Pharmacol (1993) 1.15
A comparison of the pharmacological and mechanical properties in vitro of large and small pulmonary arteries of the rat. Clin Sci (Lond) (1992) 1.08
Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation (2001) 1.07
Differential sensitivity among nitric oxide donors toward ODQ-mediated inhibition of vascular relaxation. J Pharmacol Exp Ther (2000) 1.01
Endothelin and 5-hydroxytryptamine on rat pulmonary artery in pulmonary hypertension. Eur J Pharmacol (1990) 0.98
Cyclic GMP-independent relaxation of rat pulmonary artery by spermine NONOate, a diazeniumdiolate nitric oxide donor. Br J Pharmacol (2000) 0.97
Effects of hydroxocobalamin and haemoglobin on no-mediated relaxations in the rat anococcygeus muscle. Clin Exp Pharmacol Physiol (1993) 0.97
S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br J Pharmacol (2000) 0.97
Effects of agents that inactivate free radical NO (NO*) on nitroxyl anion-mediated relaxations, and on the detection of NO* released from the nitroxyl anion donor Angeli's salt. Br J Pharmacol (2001) 0.93
Modulation of angiotensin-converting enzyme by nitric oxide. Br J Pharmacol (1998) 0.89
Physicochemistry, pharmacokinetics, and pharmacodynamics of S-nitrosocaptopril crystals, a new nitric oxide donor. J Pharm Sci (1999) 0.89
Inhibition by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of responses to nitric oxide-donors in rat pulmonary artery: influence of the mechanism of nitric oxide generation. J Pharm Pharmacol (1999) 0.89
The future of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol (1985) 0.88
S-nitrosocaptopril. I. Molecular characterization and effects on the vasculature and on platelets. J Pharmacol Exp Ther (1989) 0.87
S-nitrosocaptopril. II. Effects on vascular reactivity. J Pharmacol Exp Ther (1989) 0.84
The hemodynamic effects of S-nitrosocaptopril in anesthetized dogs. J Pharmacol Exp Ther (1991) 0.83
No-donors: an emerging class of compounds in medicinal chemistry. Farmaco (1996) 0.83
Functional effects of 4-aminopyridine (4-AP) on pulmonary and systemic vessels from normoxic control and hypoxic pulmonary hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol (1999) 0.81
Stability of captopril in some aqueous systems. J Clin Pharm Ther (1992) 0.81
Recognition and management of pulmonary hypertension. Drugs (1998) 0.80
Nitric oxide donors and angiotensin-converting enzyme inhibitors act in concert to inhibit human angiotensin-converting enzyme activity and platelet aggregation in vitro. Eur J Pharmacol (2000) 0.79
Perindopril, an angiotensin converting enzyme inhibitor, in pulmonary hypertensive rats: comparative effects on pulmonary vascular structure and function. Br J Pharmacol (1999) 0.79
Multiple pathways of angiotensin I conversion and their functional role in the canine penile corpus cavernosum. J Pharmacol Exp Ther (2001) 0.78
The effects of S-nitrosocaptopril on canine coronary circulation. J Pharmacol Exp Ther (1995) 0.78
Medical management of primary pulmonary hypertension. Expert Opin Pharmacother (2002) 0.77
Vascular chymase: pathophysiological role and therapeutic potential of inhibition. Cardiovasc Res (2004) 1.19
Vascular endothelial growth factor-B-deficient mice show impaired development of hypoxic pulmonary hypertension. Cardiovasc Res (2002) 0.93
Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate. Br J Pharmacol (2002) 0.84
Nitric oxide donors inhibit 5-hydroxytryptamine (5-HT) uptake by the human 5-HT transporter (SERT). Br J Pharmacol (2004) 0.84
Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Can J Physiol Pharmacol (2005) 0.84
Alterations in pulmonary vascular function in rats exposed to intermittent hypoxia. Eur J Pharmacol (2003) 0.83
5-Hydroxytryptamine and platelets: uptake and aggregation in hypoxic pulmonary hypertensive rats. Eur J Pharmacol (2003) 0.77
S-nitrosocaptopril: acute in-vivo pulmonary vasodepressor effects in pulmonary hypertensive rats. J Pharm Pharmacol (2003) 0.76
Potentiation of 5-hydroxytryptamine (5-HT) responses by a 5-HT uptake inhibitor in pulmonary and systemic vessels: effects of exposing rats to hypoxia. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.76
Will chymase inhibitors be the next major development for the treatment of cardiovascular disorders? Expert Opin Investig Drugs (2003) 0.76
Platelet inhibitory effects of the nitric oxide donor drug MAHMA NONOate in vivo in rats. Eur J Pharmacol (2003) 0.75